Point of care with serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) for heart failure in patients with acute decompensation. An invited commentary

被引：2

作者：

Sergi, Consolato M. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Ottawa, Childrens Hosp Eastern Ontario, Anat Pathol Div, Ottawa, ON, Canada

[2] Univ Alberta, Dept Pediat, Edmonton, AB, Canada

[3] Univ Alberta, Dept Lab Med, Edmonton, AB, Canada

[4] Univ Alberta Hosp, Stollery Childrens Hosp, Edmonton, AB, Canada

来源：

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS | 2022年 / 26卷

基金：

加拿大健康研究院;

关键词：

Point-of-care testing; Heart failure; Public health; DIAGNOSIS;

D O I：

10.1016/j.conctc.2022.100889

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Point-of-care (POC) Testing (POCT) is a medical diagnostic approach carried out outside the clinical laboratory and close to the patient. The results are used for the immediate clinical decision to improve patient care. Accreditation Canada and Diagnostic Accreditation Programs regulatory standards and the College of the American Pathologists for POCT have implemented several guidelines and certifications. POC in heart failure (POC-HF) will demonstrate that it is helpful to develop a preliminary understanding of the value of serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements in the diagnostic and therapeutic process in patients hospitalized with acute decompensation of heart failure. In addition, POC-HF will hopefully answer questions on the workability of this approach in clinical routine and the usefulness and justification to perform larger-scale studies investigating this strategy.

引用

页数：3

共 18 条

[1] MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling [J].